(Q34220221)

31 July 2017

1 reference

title

The use of biologic agents in the treatment of ocular manifestations of Behcet's disease (English)

1 reference

31 July 2017

0 references

Lucia Sobrin

2

0 references

author name string

Nicole R Benitah

series ordinal

1

1 reference

31 July 2017

George N Papaliodis

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

Seminars in Ophthalmology

31 July 2017

published in

1 reference

31 July 2017

volume

26

1 reference

31 July 2017

issue

4-5

1 reference

31 July 2017

page(s)

295-303

1 reference

Virus interference. I. The interferon

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

The use of interferon alpha in Behçet disease: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Effects of interferon alpha treatment on the clinical course of refractory Behçet's disease: an open study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Infliximab in the treatment of refractory posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Long-lasting remission of severe Behçet's disease after the end of infliximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Infliximab for the treatment of refractory Adamantiades-Behçet disease with articular, intestinal, cerebral and ocular involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Regression of optic disc neovascularization in patients with Behçet's uveoretinitis after infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Immunosuppressive therapy for ocular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Anti-TNF-α Treatment: A Possible Promoter in Endogenous Uveitis? Observational Report on Six Patients: Occurrence of Uveitis Following Etanercept Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Treatment of retinal vasculitis in Behçet's disease with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2011.588665

10.3109/08820538.2011.588665

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference